drugset / Trial / NCT05460325
A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)
NaSingle-groupOpen-labelTreatment
Summary
The main aim of this study is to evaluate the safety of lanadelumab in Chinese participants with HAE. Participants will be treated with lanadelumab for 26 weeks.
Timeline
- Start
- 2022-06-22
- Primary completion
- 2023-11-28
- Completion
- 2023-11-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lanadelumab | Monoclonal antibody | 300 mg | Subcutaneous |